FINWIRES · TerminalLIVE
FINWIRES

Revolution Medicines Says Phase 3 Daraxonrasib Trial Shows Survival Benefit in Metastatic Pancreatic Cancer

By

Revolution Medicines' (RVMD) phase 3 data for daraxonrasib showed improved overall survival and progression-free survival compared with chemotherapy in previously treated metastatic pancreatic cancer, the company said late Sunday.

The phase 3 trial met all primary and key secondary endpoints, with daraxonrasib reducing the risk of death by 60% and increasing median overall survival to 13.2 months from about 6.6 months with chemotherapy, Revolution Medicines said.

The once-daily oral therapy was generally well tolerated with a manageable safety profile, the company said.

Revolution Medicines said it plans to submit data from the trial as part of its new drug application to the US Food and Drug Administration.

Shares of Revolution Medicines were up over 10% in Monday premarket trading.

Price: $174.50, Change: $+17.02, Percent Change: +10.81%

Related Articles

Wire

Summit Therapeutics Says Ivonescimab Improves Survival Over Tislelizumab in Phase III Lung Cancer Trial

Summit Therapeutics' (SMMT) ivonescimab in combination with chemotherapy demonstrated a significant overall survival benefit over tislelizumab plus chemotherapy in the Phase III HARMONi-6 trial in previously untreated patients with advanced squamous non-small cell lung cancer, the company said Sunday.The company said ivonescimab reduced the risk of death by 34%, with patients receiving the drug plus chemotherapy achieving longer median overall survival and higher 24-month survival rates than those treated with tislelizumab plus chemotherapy.The survival benefit was consistent across both PD-L1-negative and PD-L1-positive patient groups. The study had previously met its primary endpoint of progression-free survival, the company added.The China-based trial, led by Akeso, showed no new safety concerns. Results were presented at the 2026 American Society of Clinical Oncology Annual Meeting and published in The Lancet.Summit Therapeutics shares were up over 4% in Monday premarket activity.Price: $18.41, Change: $+0.87, Percent Change: +4.97%

$SMMT
Wire

Market Chatter: Pro Medicus' New Contracts Dispel Fears Over AI Competition, RBC Capital Markets Says

Pro Medicus' (ASX:PME) two recent contract awards in the US will help discredit fears of competitors in the artificial intelligence space eroding long-term demand, RBC Capital Markets said in a note, the Australian Financial Review reported Monday.The company disclosed that US subsidiary Visage Imaging renewed its partnership with Allegheny Health Network through a five-year contract valued at around AU$28 million, and also signed a seven-year contract with TidalHealth valued at AU$16 million.The contracts show that customers remain committed to longer term deals as opposed to shorter agreements that would maintain flexibility for AI-native alternatives, RBC analyst Jackson Lee said, according to the report.The awards also add to traction seen in the company's cloud imaging platform and transaction-based revenue model, RBC reportedly said.The investment firm kept a sector perform rating on Pro Medicus with a share price target of AU$195, AFR reported.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$ASX:PME
Wire

Nova Minerals Says Shareholders, Listed Warrant Holders Approve Schemes of Arrangement for New US Holding Entity

Nova Minerals (ASX:NVA) said the majority of its shareholders and the holders of its Nasdaq-listed warrants voted in favor of the proposed schemes of arrangement under which Nova Minerals Corp will acquire all of Nova Minerals' issued ordinary shares and listed warrants and become the new US holding entity of the Nova Minerals group, according to a Monday Australian bourse filing.Nearly 99% of the votes cast by shareholders were in favor of the proposed arrangements, while almost 100% of the votes cast by beneficial listed warrant holders were in favor.A court hearing for the Supreme Court of New South Wales to consider and potentially approve the schemes of arrangement is scheduled for Tuesday.Nova Minerals' shares fell nearly 1% in early trading on Monday.

$ASX:NVA